What it's for (Indications)
- Daxibuprofen (Tercica) is indicated for the symptomatic treatment of pain and inflammation in various conditions.
- These include acute musculoskeletal pain, rheumatoid arthritis, osteoarthritis, dysmenorrhea, and other inflammatory conditions where nonsteroidal anti-inflammatory drug (NSAID) therapy is deemed appropriate.
- It provides analgesic, anti-inflammatory, and antipyretic effects by targeting the underlying inflammatory processes.
- Clinical use typically involves managing conditions where systemic inflammation or pain requires effective intervention.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | The dosage of daxibuprofen (Tercica) must be individualized based on the patient's condition, the severity of symptoms, and their response to treatment. Typically administered orally, the lowest effective dose for the shortest duration necessary to control symptoms should be used to minimize potential adverse effects. Specific dosing regimens will vary; for instance, in chronic inflammatory conditions like osteoarthritis or rheumatoid arthritis, lower maintenance doses may be appropriate after an initial higher dose for acute symptom management. For acute pain, a higher initial dose may be used, followed by reduced dosing. Prescribers should always consult the official prescribing information for detailed dose recommendations for specific indications, patient populations (e.g., elderly), and maximum daily doses. |
Safety & Warnings
Common Side Effects
- Common side effects associated with daxibuprofen (Tercica) are typical of NSAID therapy and frequently involve the gastrointestinal system, including dyspepsia, nausea, vomiting, abdominal pain, diarrhea, and constipation.
- Other potential side effects include headache, dizziness, nervousness, skin rash, fluid retention, and peripheral edema.
- More serious but less common adverse effects can involve gastrointestinal ulceration and bleeding (sometimes without warning), renal impairment (including acute kidney injury), elevated liver enzymes, hypertension, and cardiovascular thrombotic events.
- Patients should be advised to report any persistent or severe adverse reactions, especially signs of gastrointestinal bleeding or severe allergic reactions, immediately to their healthcare provider.
- Regular monitoring may be recommended for long-term use.
Serious Warnings
- Black Box Warning: **WARNING: CARDIOVASCULAR THROMBOTIC EVENTS and GASTROINTESTINAL RISK** **Cardiovascular Thrombotic Events:** Nonsteroidal anti-inflammatory drugs (NSAIDs), including daxibuprofen (Tercica), increase the risk of serious cardiovascular thrombotic events, including myocardial infarction (MI) and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use. Patients with known cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. Daxibuprofen is contraindicated in the setting of coronary artery bypass graft (CABG) surgery, as NSAIDs significantly increase the risk of adverse cardiovascular events post-surgery. Healthcare professionals should carefully assess cardiovascular risk factors before prescribing and periodically during treatment. **Gastrointestinal Risk:** NSAIDs, including daxibuprofen, increase the risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use, often without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI bleeding are at greater risk for serious GI events. To minimize these risks, the lowest effective dose of daxibuprofen should be used for the shortest duration possible. Concomitant use with aspirin, corticosteroids, or other NSAIDs may further increase GI risk.
- Beyond the critical Black Box Warnings, daxibuprofen (Tercica) carries several other important safety warnings.
- Patients with a history of asthma, particularly aspirin-sensitive asthma, may experience severe, sometimes fatal, bronchospasm or other hypersensitivity reactions.
- Caution is advised in patients with pre-existing hypertension, fluid retention, or congestive heart failure, as NSAIDs can exacerbate these conditions.
- Renal function should be closely monitored, especially in elderly patients or those with pre-existing renal impairment, heart failure, or cirrhosis, due to the risk of dose-dependent renal toxicity.
- Liver function should also be periodically assessed as elevated liver enzymes and, rarely, severe liver reactions can occur.
- Anaphylactoid reactions, sometimes severe, can occur in patients with no known prior exposure.
- Use in pregnant women (especially during the third trimester) is strongly discouraged due to the risk of premature closure of the fetal ductus arteriosus and potential renal dysfunction in the fetus.
- Caution is also advised during lactation, as NSAIDs can be excreted into breast milk.
How it Works (Mechanism of Action)
Daxibuprofen, the S(+)-enantiomer of ibuprofen, exerts its primary therapeutic effects through the reversible inhibition of cyclooxygenase (COX) enzymes, specifically both COX-1 and COX-2 isoforms. This inhibition leads to a significant reduction in the synthesis of prostaglandins, which are crucial lipid mediators involved in the pathophysiology of pain, inflammation, and fever. By decreasing prostaglandin production at sites of injury and inflammation, daxibuprofen effectively provides analgesic, anti-inflammatory, and antipyretic relief. Its pharmacological activity as the predominant active enantiomer of ibuprofen contributes to its efficacy and specific pharmacokinetic profile.
Commercial Brands (Alternatives)
No other brands found for this formula.